Septic Shock - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Septic Shock - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Septic Shock - Pipeline Review, H1 2016', provides an overview of the Septic Shock pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septic Shock
- The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
- The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Septic Shock

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Septic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Septic Shock Overview 9
Therapeutics Development 10
Pipeline Products for Septic Shock - Overview 10
Pipeline Products for Septic Shock - Comparative Analysis 11
Septic Shock - Therapeutics under Development by Companies 12
Septic Shock - Therapeutics under Investigation by Universities/Institutes 14
Septic Shock - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Septic Shock - Products under Development by Companies 18
Septic Shock - Products under Investigation by Universities/Institutes 19
Septic Shock - Companies Involved in Therapeutics Development 20
Adrenomed AG 20
Ferring International Center S.A. 21
Huons Co., Ltd. 22
InflaRx GmbH 23
Leading BioSciences, Inc. 24
Lixte Biotechnology Holdings, Inc. 25
Noxxon Pharma AG 26
Orion Oyj 27
Peptinov SAS 28
Pharmazz, Inc. 29
Spider Biotech 30
Takeda Pharmaceutical Company Limited 31
ViiV Healthcare Limited 32
XImmune AB 33
Septic Shock - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
adrecizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AM-12 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BC-1215 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BMS-936559 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BTZO-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
C-10 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drug for Sepsis and Septic Shock - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HBN-1 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HBN-3 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
HBN-4 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
HU-003 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
IFX-1 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
L-257 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LB-100 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LB-1148 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
levosimendan - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NOXD-21 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PMZ-2010 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
R-190 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SB-056 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
selepressin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SP-14 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SP-9 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Septic Shock - Recent Pipeline Updates 74
Septic Shock - Dormant Projects 81
Septic Shock - Discontinued Products 83
Septic Shock - Product Development Milestones 84
Featured News & Press Releases 84
Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 84
Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 84
Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 85
Feb 02, 2015: Leading BioSciences Recieves FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock 87
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Septic Shock, H1 2016 10
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Septic Shock - Pipeline by Adrenomed AG, H1 2016 20
Septic Shock - Pipeline by Ferring International Center S.A., H1 2016 21
Septic Shock - Pipeline by Huons Co., Ltd., H1 2016 22
Septic Shock - Pipeline by InflaRx GmbH, H1 2016 23
Septic Shock - Pipeline by Leading BioSciences, Inc., H1 2016 24
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 25
Septic Shock - Pipeline by Noxxon Pharma AG, H1 2016 26
Septic Shock - Pipeline by Orion Oyj, H1 2016 27
Septic Shock - Pipeline by Peptinov SAS, H1 2016 28
Septic Shock - Pipeline by Pharmazz, Inc., H1 2016 29
Septic Shock - Pipeline by Spider Biotech, H1 2016 30
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 31
Septic Shock - Pipeline by ViiV Healthcare Limited, H1 2016 32
Septic Shock - Pipeline by XImmune AB, H1 2016 33
Assessment by Monotherapy Products, H1 2016 34
Number of Products by Stage and Target, H1 2016 36
Number of Products by Stage and Mechanism of Action, H1 2016 38
Number of Products by Stage and Route of Administration, H1 2016 40
Number of Products by Stage and Molecule Type, H1 2016 42
Septic Shock Therapeutics - Recent Pipeline Updates, H1 2016 74
Septic Shock - Dormant Projects, H1 2016 81
Septic Shock - Dormant Projects (Contd..1), H1 2016 82
Septic Shock - Discontinued Products, H1 2016 83